

## Colon Cancer

CHI Formulary Treatment algorithm

Treatment algorithm-November 2023

Supporting treatment algorithms for the clinical management of Colon Cancer

Figure 1 to 7 outline a comprehensive treatment algorithm on **Colon Cancer**, aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Colon Cancer** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at <a href="https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx">https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx</a>

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.




Figure 1: ESMO 2022 Recommendations for Adjuvant Treatment of Stage II Colon Cancer

¹ Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003




Figure 2: ESMO 2020 Recommendations for Adjuvant Treatment of Stage III Colon Cancer

<sup>2</sup> Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003




Figure 3: ESMO 2022 Local Treatment of CRC Metastases

<sup>3</sup> Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003




Figure 4: ESMO 2022 Management of Stage IV Unresectable mCRC in First-Line Therapy

<sup>4</sup> Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003




Figure 5: ESMO 2022 Management of Stage IV Unresectable mCRC with Maintenance Therapy

\_

<sup>&</sup>lt;sup>5</sup> Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003




Figure 6: ESMO 2022 Management of Stage IV Unresectable mCRC in the Second Line

<sup>6</sup> Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003




Figure 7: ESMO 2022 Management of Stage IV Unresectable mCRC in Third-Line Therapy and Beyond

<sup>7</sup> Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003